Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022:

• Jefferies 2022 Global Healthcare Conference in New York, NY
  Friday, June 10, 2022
  Fireside chat at 10:00 am Eastern Time

• JMP Securities Life Sciences Conference in New York, NY
  Thursday, June 16, 2022
  Fireside chat at 9:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.